Medicsight PLC (AIM:MDST) – May 14, 2008 – industry leader in the development of Computer-Aided Detection (CAD) and image analysis software which assists in the early detection and diagnosis of disease, is pleased to announce the appointment of Nomura Code Securities Limited as Nominated Adviser (NOMAD) and sole broker to the Company with immediate effect.

David Sumner, CEO of Medicsight, commented on the appointment: "The Board is very impressed with Nomura Code's market knowledge and specialist investor links in the healthcare sector. Nomura Code has significant outreach in Japan, which will be very beneficial to Medicsight as we penetrate the Asian market and continue to develop strong relations with Toshiba."

Juliet Thompson, Managing Director, Corporate Finance, Nomura Code Securities Limited, said: "We have been actively interested in Medicsight since its flotation in June 2007 and are delighted to cement this interest with a formal appointment. The Medicsight story is extremely compelling and we look forward to working with Medicsight towards further growth."

For Further Information:
Medicsight PLC
David Sumner, CEO
Tel: +44 (0)20 7605 7950
www.medicsight.com

Nomura Code Securities Limited
Juliet Thompson, Managing Director
Tel: +44 (0)20 777 61200

Jon Senior
www.nomuracode.com

Media enquiries:
Abchurch
Tel: +44 (0) 20 7398 7700

Heather Salmond
Tel: +44 (0) 20 7398 7704
heather.salmond@abchurch-group.com

Stephanie Cuthbert / Simone Alves
Tel: +44 (0) 20 7398 7718
stephanie.cuthbert@abchurch-group.com
www.abchurch-group.com

Notes to Editors

Medicsight PLC is a UK headquartered, research driven, leading developer of computer-aided detection (CAD) and image analysis software for the medical imaging market. The CAD software automatically highlights suspicious areas on computerised tomography (CT) scans of the colon and lung, helping radiologists to identify, measure and analyse potential disease and early indicators of disease. Medicsight's computer-aided detection (CAD) software has been validated using one of the world's largest and most population diverse databases of verified patient CT scan data. Medicsight's ColonCAD™ and LungCAD™ software products are seamlessly integrated with the advanced 3D visualisation workstations of several industry-leading imaging equipment partners.

About Computer-Aided Detection

With increasingly sophisticated radiological imaging hardware such as Multi-Detector CT scanners, radiologists are facing a growing challenge in the amount of detailed patient image data that they must review for each patient examination. Some CT scan examinations generate as many as 1000 images per patient. Review of this data by the radiologist is not only time-consuming but also prone to error due to reader fatigue. CAD software can help the reviewing radiologist by analysing the image data and automatically highlighting suspicious regions of interest for closer inspection. Without CAD software some potential abnormalities or areas of disease may be overlooked. This is critical for diagnosis and the management of patient outcomes as early detection of disease greatly increases the probability of successful treatment and a positive therapeutic outcome.

About Medicsight's CAD Software

Medicsight's ColonCAD™ and LungCAD™ software use an advanced CAD algorithm to analyse CT scans of the colon and lung and automatically highlight suspicious areas that may be indicators of disease. CAD may highlight areas easily overlooked by the reviewing radiologist, such as small lesions or regions that are hidden from view behind folds in the colon or normal structures and surrounding tissue in the lung.

Both CAD products seamlessly integrate with the advanced 3D visualisation platforms of industry-leading imaging equipment partners. The integrated systems provide sophisticated image viewing capabilities, including 3D reconstructed image data, with the added advantage of demonstrating automatic CAD findings to assist clinical end users in the detection and analysis of disease. This allows clinical end users to perform either a 'second read', where CAD findings are displayed to the user after completion of an initial review of the CT scan data, or a 'concurrent read' where CAD findings are displayed during the user's initial review of the original CT scan images.

Since inception, Medicsight has developed close and lasting relationships with some of the world's foremost clinicians in product related areas. This provides the Company with a wealth of clinical expertise and dedicated clinical research to support ongoing product development. Medicsight also collaborates with a number of leading academic institutions and clinical research programmes worldwide to develop the Company's comprehensive database of population diverse verified patient CT scan data, thus allowing Medicsight's products to be validated to the highest possible standards.

About ACRIN 6664

The preliminary results of the National US Computerised Tomography (CT) Colonography Trial (ACRIN study 6664), released on 28 September, demonstrated convincingly that CT colonography is at least as sensitive and specific as conventional optical colonoscopy in detecting adenomas of 1 cm diameter or larger. A few days later another major study was published in the prestigious New England Journal of Medicine with a similar outcome. These compelling results from two large well-controlled studies are expected to lead to widespread adoption of CT colonography (also known as virtual colonoscopy) as routine primary screening for colorectal cancer.